Last update 12 Sep 2024

Sulanemadlin

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
ALRN 6924, ALRN-6924
Mechanism
MDM2 inhibitors(p53-binding protein Mdm-2 inhibitors), MDMX inhibitors(Protein Mdm4 inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-

Structure

Molecular FormulaC95H140N20O23
InChIKeyVDLGAZDAHPLOIR-RLPDZDIMSA-N
CAS Registry1451199-98-6

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-Small Cell Lung CancerPhase 2
US
03 Sep 2019
Non-Small Cell Lung CancerPhase 2
BA
03 Sep 2019
Non-Small Cell Lung CancerPhase 2
PL
03 Sep 2019
Non-Small Cell Lung CancerPhase 2
RS
03 Sep 2019
Non-Small Cell Lung CancerPhase 2
ES
03 Sep 2019
Chemotherapy-induced damagePhase 2
HR
14 Aug 2019
Hematologic NeoplasmsPhase 2
US
31 Jul 2016
Advanced Malignant Solid NeoplasmPhase 2
US
01 Oct 2014
Peripheral T-Cell LymphomaPhase 2
US
01 Oct 2014
Chemotherapy-induced myelosuppressionPhase 1
US
09 Jan 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
20
vtbcpcssvj(sijiqrhyoz) = xzuqzflyym mzwzaixgtj (wqtospfzts )
Negative
29 Jun 2022
vtbcpcssvj(sijiqrhyoz) = csywqgzhkc mzwzaixgtj (wqtospfzts )
Phase 1
44
fcyhfmhlhu(amipdinlqr) = uksvptuqyj nbbrmbfyme (cpbhlutksr )
Positive
16 Sep 2021
fcyhfmhlhu(amipdinlqr) = morvbuuboc nbbrmbfyme (cpbhlutksr )
Phase 1
Solid tumor | Lymphoma
TP53 Wild-type
71
(arm A)
cvulmoiofe(scyddoiusq) = rkgtilgwal qyxovzegqy (hdwfbzftsj )
Positive
22 Jul 2021
(arm B)
mpwcmxqkje(cytuifksvh) = lmetmudoxi ovmciwohuc (vafelepdgm )
Phase 2
Neoplasms
TP53 Wild-type | MDM2 Amplification | CDK4 Amplification
12
ALRN-6924+palbociclib
hzpzfaltxb(flhyrmkpnf) = neutropenia, thrombocytopenia, leukopenia, increased ALT, pulmonary embolism, and fall fnpoyiqbln (pdeewerwbv )
Positive
28 Sep 2019
Phase 1
69
wfiooizere(yhmkdbjach) = DLTs were G3 fatigue at 3.1 mg/kg, and G3 hypotension, G3 alkaline phosphatase elevation, G3 anemia and G4 neutropenia at 4.4 mg/kg all in 5 pts in arm A. No G3/4 thrombocytopenia was observed. All DLTs resolved with dose hold. xjsueehvvt (zjroyeaesc )
Positive
30 May 2017
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free